Deutsche Bank AG Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Deutsche Bank AG increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,321,633 shares of the medical research company's stock after buying an additional 114,277 shares during the period. Deutsche Bank AG owned about 0.35% of Thermo Fisher Scientific worth $687,553,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. Principal Financial Group Inc. increased its position in Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after purchasing an additional 225,568 shares during the period. Nordea Investment Management AB increased its position in shares of Thermo Fisher Scientific by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after buying an additional 10,606 shares during the period. Bangor Savings Bank raised its stake in Thermo Fisher Scientific by 6.0% during the fourth quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock worth $174,000 after buying an additional 19 shares during the last quarter. Fulton Bank N.A. lifted its holdings in Thermo Fisher Scientific by 3.7% in the fourth quarter. Fulton Bank N.A. now owns 8,161 shares of the medical research company's stock valued at $4,246,000 after buying an additional 288 shares during the period. Finally, Douglas Lane & Associates LLC raised its position in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company's stock worth $94,948,000 after acquiring an additional 3,460 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

TMO has been the subject of several recent analyst reports. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, StockNews.com lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $607.43.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $7.85 during mid-day trading on Friday, reaching $402.93. 2,318,607 shares of the company's stock were exchanged, compared to its average volume of 1,799,554. The firm has a market capitalization of $152.10 billion, a PE ratio of 24.38, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business's fifty day simple moving average is $464.67 and its 200 day simple moving average is $514.85. Thermo Fisher Scientific Inc. has a one year low of $401.75 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the firm earned $5.11 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were given a $0.43 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock valued at $7,305,942 in the last 90 days. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.